Prolonged regulatable expression of EPO from an HSV vector using the LAP2 promoter element

Area of Science:

• Neuroscience
• Gene Therapy
• Molecular Biology

Background:

• Peripheral neuropathy, particularly diabetic neuropathy, is a significant clinical challenge.
• Regulated gene expression systems are crucial for developing safe and effective gene therapies.

Purpose of the Study:

• To develop a herpes simplex virus (HSV)-based vector for inducible erythropoietin (EPO) expression in the peripheral nervous system.
• To evaluate the efficacy of this vector in a mouse model of diabetic neuropathy.

Main Methods:

• Construction of an HSV vector with a Tet-on system for EPO expression, driven by the HSV latency-associated promoter 2.
• In vitro and in vivo studies involving doxycycline (DOX) administration to control EPO expression.
• Assessment of neuropathy development in streptozotocin-induced diabetic mice transduced with the HSV-EPO vector.

Main Results:

• Tightly regulated EPO expression was achieved in vitro and in vivo via DOX administration.
• Continuous DOX administration for 3 months protected diabetic mice from neuropathy.
• Intermittent DOX administration (every other week) provided similar protection, while less frequent administration (1 week out of 3) offered partial protection.

Conclusions:

• The developed HSV-EPO vector allows for controlled gene expression suitable for treating chronic or subacute neuropathies.
• The dosing frequency of DOX influences the protective effect against neuropathy.
• This vector system holds promise for clinical trials in neuropathy treatment.